This is our largest site with 70+ employees and a continuous production of 100+ PXB-mice per week. In addition to in vivo study services for NAFLD/NASH, viral hepatitis, gene-based therapeutics, DMPK/toxicology, and custom transplantations, we also offer HBV study services at this location.
This office is responsible for all non-Japanese clients. We complete project management, marketing, and sales from this office.
This is a production facility for PXB-mice and PXB-cells.
The Chimeric Mouse with a Humanized Liver (CMHL) Consortium was started by PhoenixBio to work with pharmaceutical industry and academic leaders to enhance applications and translational research using the PXB-mouse model. As of 2021, a total of 11 institutions, including eight pharmaceutical companies, are participating in the research.
|Company Name||PhoenixBio Co., Ltd.|
|Established||March 4th, 2002|
|President and CEO||Takashi Shimada|
|Capital||22.165 million USD (Mar.2021)|
|Headquarters||3-4-1 Kagamiyama, Higashi-Hiroshima City 739-0046 Japan|
|PhoenixBio USA Corporation||65 Broadway, Suite 605, New York NY, 10006 USA
|KMT Hepatech Inc.
2011-94 Street NW, Edmonton, Alberta, Canada, T6N1H1
|CMHL Consortium LLC
At PhoenixBio, our team strives to improve the global population’s quality of life and health through the application of our chimeric mouse model with a humanized liver. Our drive to improve the population’s health is central to the work we do to advance preclinical research and therapeutic development.
|Takashi Shimada:||President & CEO|
|Yasuhiro Tamura:||Executive Director of Administration|
|Chise Tateno-Mukaidani, Ph.D.:||Executive Director of Research and Development|
|Masakazu Kakuni, D.V.M., Ph.D.:||Executive Director (President, KMT Hepatech Inc.)|
|Yoshio Morikawa:||Executive Director (President & CEO, PhoenixBio USA Corporation)|
|Yoshinori Fujii:||External Director|
|Masaharu Sagara:||Full-time auditor|